L-I-OddU, a potent and selective anti-Epstein-Barr virus (EBV) agent, is a L-5'-halo-dioxolane nucleoside analogue. It demonstrates antiviral activity by effectively suppressing replicative EBV DNA and viral protein synthesis [1] [2]. With an EC 50 value of 0.03 μM, L-I-OddU exhibits high potency against EBV while maintaining low cytotoxicity, as indicated by its CC 50 value of 1000 nM.

L-I-OddU, at a concentration of 1 μM in H1 cells, impedes the replication of the Epstein-Barr virus (EBV) and reduces the linear form of EBV DNA [1]. When administered to H1 and L5 cells at doses ranging from 0.25 to 2 μM for 24 hours, L-I-OddU predominantly metabolizes into L-I-OddUMP and elevates the production of mono- and diphosphate metabolites in H1 cells in a dose-dependent fashion [1].